Combining Carmustine and TNF for Melanoma Treatment
Author Information
Author(s): A.L. Jones, J.L. Millar, B.C. Millar, B. Powell, P. Selby, A. Winkley, S. Lakhani, M.E. Gore, T.J. McElwain
Primary Institution: Royal Marsden Hospital
Hypothesis
Does the combination of carmustine and TNF enhance anti-tumor activity in melanoma?
Conclusion
The combination of carmustine and TNF significantly delays tumor growth in melanoma without increasing toxicity.
Supporting Evidence
- BCNU alone was cytotoxic to murine B16 melanoma cells.
- The addition of TNF increased the cytotoxicity of BCNU.
- In vivo, the combination treatment resulted in significant growth delay compared to either drug alone.
- No significant increase in toxicity was observed with the combination treatment.
Takeaway
Using two medicines together can help fight melanoma better than using just one, and it doesn't make the side effects worse.
Methodology
The study involved in vitro and in vivo experiments using murine and human melanoma models to assess the effects of carmustine and TNF.
Limitations
The study was conducted in animal models, which may not fully represent human responses.
Participant Demographics
Female C57 BL mice and male 'nude' mice were used in the experiments.
Statistical Information
P-Value
0.001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website